Invivo Capital, a life-sciences venture capital firm based in Barcelona and CataloniaBio & HealthTech member, has invested €2 million in Pulmobiotics, a company developing new drugs for lung infections using synthetic biology tools.

Pulmobiotics was set up this year as a spin-off of the Centre for Genomic Regulation (CRG) by Dr Luis Serrano and Dr María Lluch, who highlight “the importance of finding new ways to treat and protect ourselves against infectious agents, as illustrated by the current Covid-19 pandemic.” This report from the Innovadores supplement of newspaper La Razón (in Spanish) explains in more detail.

Respiratory diseases (chronic obstructive pulmonary disease, pneumonia, asthma) are one of the main causes of death in the European Union.

Dr LluísPareras, physician and founding partner of Invivo Capital, believes “even in the current circumstances, science can’t and shouldn’t stop.”

Albert Ferrer, also a founding partner of Invivo, explains that “we want to support technology transfer from research centres and encourage development of innovative products. This investment in Pulmobiotics is a clear example of our vision and we are satisfied because it will create a new business and fivenew jobs in science.”

Photo: Invivo Capital team